Stephen R. Saklad, PharmD, BCPP

  • 7Articles
  • 19.4KReads
  • 2020–2025Active
  • 13Collaborators
  • 48Citations

About

Stephen R. Saklad, PharmD, BCPP, is affiliated with the Division of Pharmacotherapy and Translational Science at the College of Pharmacy, The University of Texas at Austin, San Antonio, Texas. Between 2020 and 2025, Saklad authored seven articles focusing on the clinical application and optimization of aripiprazole monohydrate long-acting injectables for bipolar disorder, schizophrenia, and schizoaffective disorders. Additional topics include the impact of olanzapine/samidorphan on weight gain and the identification and treatment of tardive dyskinesia. Saklad frequently collaborates with Christoph U. Correll, Eric D. Achtyes, Joseph F. Goldberg, Martha Sajatovic, and Daniel Still.

Publications

JCP
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

August 13, 2025

A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
, , , et al
JCP
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

August 13, 2025

A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
, , , et al
JCP
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
Academic Highlights

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

June 13, 2025

A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
, , , et al
JCP
Olanzapine/Samidorphan Effects on Weight Gain
Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...
, , , et al
JCP
Aripiprazole Lauroxil Initiation Regimens
Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.
, , , et al
JCP
Academic Highlights

Evaluating and Treating Tardive Dyskinesia

February 18, 2020

What should you rule out to diagnose tardive dyskinesia (TD)? How do treatment options differ? In this journal CME activity, Drs Citrome and Saklad team up to review the...
,
JCP
Educational Activity

Evaluating Patients for Tardive Dyskinesia

January 14, 2020

Tardive dyskinesia must be detected early to minimize the risk of permanence. Do you know how often to screen patients and how to conduct an evaluation? Dr Stephen Saklad...

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe